Previous 10 | Next 10 |
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml. ANI’s Nitrofurantoin Oral Suspension is th...
2023-04-04 07:29:16 ET The U.S. Food and Drug Administration (FDA) approved ANI Pharmaceuticals' ( NASDAQ: ANIP ) generic cholesterol-lowering drug, Colestipol Hydrochloride Tablets USP 1 g. The company said its Colestipol Hydrochloride tablets are the generic version of the r...
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Colestipol Hydrochloride Tablets USP, 1 g. ANI’s Colestipol Hydrochloride Tablets are the ...
2023-03-10 17:31:23 ET Amid concerns about smaller pharma and biotech companies' exposure to Silicon Valley Bank ( SIVB ), a number of them have disclosed that they have no relationship with the FDIC-shuttered financial institution . Among the larger ones are Cara Therapeu...
2023-03-09 13:10:20 ET ANI Pharmaceuticals, Inc. (ANIP) Q4 2022 Earnings Conference Call March 09, 2023, 08:30 ET Company Participants Judy DiClemente - IR Nikhil Lalwani - President, CEO & Director Stephen Carey - CFO, SVP, Finance & Corporate Secretary ...
2023-03-09 06:52:38 ET ANI Pharmaceuticals press release ( NASDAQ: ANIP ): Q4 Non-GAAP EPS of $0.76 beats by $0.09 . Revenue of $94.2M (+54.7% Y/Y) beats by $8.06M . Cash and cash equivalents were $48.2 million, net accounts receivable was $165.4 million, and f...
Fourth Quarter and Full Year 2022 Financial Results -- Q4 net revenues of $94.2 million, net loss available to common shareholders of $(4.7) million and diluted GAAP loss per share of $(0.28) – -- Q4 Adjusted non-GAAP EBITDA of $23.3 million and adjusted non-GAAP diluted ...
2023-03-08 13:03:50 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q4 earnings results on Thursday, March 9th, before market open. The consensus EPS Estimate is $0.67 (+24.1% Y/Y) and the consensus Revenue Estimate is $86.14M (+41.4% Y/Y). Over the la...
2023-03-08 10:27:33 ET Major earning expected before the bell on Thursday include: Arrival ( ARVL ) FuelCell Energy ( FCEL ) JD.com ( JD ) Paysafe ( PSFE ) Village Farms International ( VFF ) For further details see: Notable earnings befor...
ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...
News, Short Squeeze, Breakout and More Instantly...
ANI Pharmaceuticals Inc. Company Name:
ANIP Stock Symbol:
NASDAQ Market:
ANI Pharmaceuticals Inc. Website:
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched L-Glutamine Oral Po...
2024-07-09 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) and launched Naproxen Delayed-Release Tablets, USP....